# A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

> **NCT06071871** · PHASE2 · RECRUITING · sponsor: **University College, London** · enrollment: 99 (estimated)

## Conditions studied

- Large B-cell Lymphoma

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Polatuzumab vedotin
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT06071871
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-16
- **Primary completion:** 2027-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06071871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06071871, "A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06071871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*